DTCFF (Defence Therapeutics) LT-Debt-to-Total-Asset: 0.17 (As of Mar. 2026)


DTCFF Defence Therapeutics Inc DTCFF
21 GF Score
Price $0.30
! 1 Warning Sign
View Full Analysis

What is Defence Therapeutics LT-Debt-to-Total-Asset?

Defence Therapeutics DTCFF -12.23% 21 LT-Debt-to-Total-Asset is 0.17 as of Mar. 2026. GuruFocus rates DTCFF with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Defence Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.17.

Defence Therapeutics's long-term debt to total assets ratio increased from Mar. 2025 (0.00) to Mar. 2026 (0.17). It may suggest that Defence Therapeutics is progressively becoming more dependent on debt to grow their business.

Defence Therapeutics  (OTCPK:DTCFF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Defence Therapeutics LT-Debt-to-Total-Asset Related Terms

Defence Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Defence Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Defence Therapeutics LT-Debt-to-Total-Asset Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.00 0.00 0.49 3.49 0.90

Defence Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.90 0.51 1.09 0.17
DTCFF
21GF Score
Defence Therapeutics Inc DTCFF
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Defence Therapeutics LT-Debt-to-Total-Asset Calculation

Defence Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (A: Jun. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2025 )/Total Assets (A: Jun. 2025 )
=1.089/1.209
=

Defence Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=1.14/6.885
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.17 mean?
Defence Therapeutics (DTCFF) has a LT-Debt-to-Total-Asset of 0.17 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Defence Therapeutics and its competitors.
Is Defence Therapeutics' LT-Debt-to-Total-Asset too high?
Defence Therapeutics' current LT-Debt-to-Total-Asset is 0.17. Overall, Defence Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Defence Therapeutics' LT-Debt-to-Total-Asset compare to VRTX and REGN?
Defence Therapeutics' LT-Debt-to-Total-Asset of 0.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Defence Therapeutics and its competitors. Defence Therapeutics's current LT-Debt-to-Total-Asset is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Defence Therapeutics stock overvalued right now?
Defence Therapeutics (DTCFF) has a current LT-Debt-to-Total-Asset of 0.17. The current LT-Debt-to-Total-Asset is 0.17. Defence Therapeutics' overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Defence Therapeutics (DTCFF), the current LT-Debt-to-Total-Asset is 0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Defence Therapeutics Business Description

Other Exchanges DTC:GermanyDTC:Canada
Address 7171 Frederick Banting Street, Montreal, QC, CAN, H4S 1Z9
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development. It operates only in Canada.
21GF Score

Get the complete analysis for DTCFF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30
Price